Network Bio raises $50M to build disease-specific AI models
What's the deal? Network Bio, a Boston-based biotechnology company, has raised $50 million in financing. Backers include Section 32, Thiel BioDealroom has a profile for this one. Try Dealroom →, Founders Fund, Breyer Capital, Blue Venture FundDealroom has a profile for this one. Try Dealroom →, and JSL Health CapitalDealroom has a profile for this one. Try Dealroom →, among other life science and AI funds.
What does it do? Led by chief executive officer Asad Ali Ahmad, the company builds disease-specific AI models trained on large-scale tissue, blood, molecular, and clinical datasets. Its platform is designed to learn biological principles that transfer across diseases, tissues, and data modalities.
What's the endgame? Network Bio will use the funds to expand its life science platform. Its approach combines a research network — partnered with academic biobanks including Mass General BrighamDealroom has a profile for this one. Try Dealroom →, the University of PennsylvaniaDealroom has a profile for this one. Try Dealroom →, and the University of Colorado AnschutzDealroom has a profile for this one. Try Dealroom → — with a bio-native AI architecture built to extract interpretable representations of disease biology.
The signal: The round underscores continued investor appetite for startups applying AI to biological data, with a roster spanning both dedicated life science and AI backers.
Read more: FinSMEs
Image credit: Idaho National Laboratory
